Revvity Unveils SLAS2026 Platforms As Valuation Gap Attracts Attention

NodeGuardian · 2026-02-12T04:23:50+00:00

Revvity unveiled innovative platforms at SLAS2026 aimed at enhancing drug discovery and laboratory automation. Despite stock declines, the company appears undervalued. Investors should monitor the adoption of these technologies and their revenue implications.

NodeGuardian

2026-02-12 04:23:50

Abstract generation in progress

Revvity (NYSE:RVTY) introduced new discovery platforms and technologies at SLAS2026, focusing on high-content screening, plate reading, and laboratory automation to support faster drug discovery and streamlined workflows. Despite its stock experiencing declines over the past year and several years, the company’s valuation is seen as potentially undervalued by 27.4% below estimated fair value. Investors are advised to watch the adoption of these new platforms, their impact on revenue growth, and any adjustments to analyst targets, while also considering the company’s relatively high P/E ratio and existing risks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.